The COVID-19 pandemic has unlocked India’s vast potential in the field of life sciences and biotechnology. The pandemic has acted as a catalyst in nurturing an ecosystem of innovation within the country and expanding research and development. One such outcome of this is the invention of Scalene Hypercharge Corona Canon (SHYCOCAN), a scientific device with the ability to contain the spread of coronavirus.
Speaking after launching the product, the inventor and the Chairman of the group Dr Rajah Vijay Kumar said: “SHYCOCAN is proven to be 99.9% effective in neutralising the Spike-Protein or S-protein that are present in coronavirus. The device is designed to release a very high concentration of environmentally safe electrons using proprietary Photon-Mediated Electron Emitters (PMEEs) made with a superalloy developed by us, to emit and excite photons with the required kinetic energy. As the high energy photons bombard bulk surfaces and suspended particles in confined environments, the electron cloud actively ‘disarms’ air and surface transmission of the Corona family of viruses. Even if an infected individual were to walk into the room, these electrons would neutralise the potency of the virus present in aerosols while sneezing or coughing. We have received approvals from the US Food and Drug Administration (FDA) and the European Union Confirmit Europenne.”
The device is effective in closed spaces of up to 1,000 sq ft or in places up to 10,000 cubic metres, such as waiting rooms, offices, malls and other public areas. The basic principle behind the technology is to disable the homing mechanism on the virus and prevent infectivity. SHYCOCAN does not harm any living organism, be it fungi or a human. It can be used in all environments and does not have any detrimental effects. SHYCOCAN does not alter or interrupt any other services and functions, be it telephone calls or internet connections.
During the virtual session, the group CEO Debashis Bose said: “We are producing and distributing the devices across India and are planning to sell around 1,30,000 SHYCOCAN device in the next six months. By the end of FY 21, we are looking for revenue of 250 crores.”